Recruiting
Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis - RPC01-3102
Oppdatert: 21 januar, 2021 | ClinicalTrials.gov
Fase
Kjønn
Aldersgruppe
Sted(er)
Recruiting
Inclusion Criteria: - Aged 18 to 75 years (at screening for Cohorts 1 and 2) - Male of Female adolescent patients aged 12 to < 18 years (at screening) with a body weight > or = 45kg (Cohort 3) - Ulcerative colitis confirmed on endoscopy - Moderately to severely active ulcerative colitis (Mayo score 6-12) - Currently receiving treatment with aminosalicylates, prednisone or budesonide - Can be receiving azathioprine, mercaptopurine, or methotrexate but treatment will be stopped prior to randomization Exclusion Criteria: - Have severe extensive colitis as evidenced by: - Physician judgement that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline - Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation - Diagnosis of Crohn's disease, indeterminate colitis, or the presence of a fistula consistent with Crohn's disease or microscopic colitis, radiation colitis, or ischemic colitis - Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk - History of uveitis or known macular edema - Pregnancy, lactation, or a positive serum B-hCG measured during screening
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046
